Analyze Pathology INC.

Analyze Pathology INC. was paid $7.31M by Medicaid between Sep 2020 and Dec 2024, across 93 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 27% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#11 of 225

Median peer was paid$74K

This provider vs. median99×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	1,891	$128K
2021	10,900	$765K
2022	52,616	$2.36M
2023	21,030	$2.11M
2024incomplete	27,253	$1.94M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	27%	14,858	9,133	$2.00M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	19%	12,850	6,182	$1.41M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	11%	13,183	4,314	$826K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	6.8%	11,977	6,181	$496K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	6.7%	7,872	4,395	$492K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	5.2%	4,008	1,723	$381K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	3.9%	2,175	1,029	$288K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.8%	13,098	4,272	$274K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3.6%	13,297	4,311	$261K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.4%	3,856	1,126	$175K
88377		2.2%	658	172	$162K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.9%	2,767	1,798	$142K

81 more codes

87634		1.4%	2,171	$106K
87529		<1%	957	$27K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	840	$20K
88312		<1%	141	$19K
87481		<1%	1,017	$17K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,067	$15K
81249		<1%	44	$14K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,030	$13K
87653		<1%	564	$11K
87511		<1%	723	$10K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	766	$10K
81317		<1%	18	$10K
81307		<1%	18	$10K
81292		<1%	18	$10K
87563		<1%	437	$9K
81298		<1%	18	$9K
81351		<1%	18	$9K
81321		<1%	18	$9K
81302		<1%	18	$8K
88342		<1%	303	$7K
81223		<1%	18	$7K
81295		<1%	18	$5K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	392	$4K
88313		<1%	304	$4K
81165		<1%	16	$4K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	49	$4K
81218		<1%	18	$3K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	118	$3K
81275		<1%	18	$3K
81233		<1%	18	$3K
81216		<1%	16	$2K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	150	$2K
81232		<1%	12	$2K
87640		<1%	115	$2K
81270		<1%	18	$1K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	22	$1K
81243		<1%	18	$821.34
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	83	$692.51
81291		<1%	13	$679.51
80074		<1%	33	$654.87
81241		<1%	26	$645.59
81209		<1%	18	$565.92
87625		<1%	48	$527.32
87522	Neg quan hep c or qual rna	<1%	36	$492.68
86803		<1%	42	$392.93
80061	Lipid panel	<1%	54	$227.70
80053	Comprehensive metabolic panel	<1%	42	$200.42
84443	Thyroid stimulating hormone (TSH)	<1%	28	$182.28
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	61	$158.27
86762		<1%	36	$156.14
83036	Hemoglobin; glycosylated (A1C)	<1%	52	$151.00
86592		<1%	94	$128.50
87340		<1%	37	$127.66
81001		<1%	78	$124.33
86850		<1%	36	$113.40
81025		<1%	28	$101.14
82248		<1%	57	$94.87
83992		<1%	23	$87.80
87641		<1%	15	$66.67
87500		<1%	14	$66.67
86900		<1%	38	$39.13
86901		<1%	37	$36.89
80354		0%	30	$0.00
80321		0%	30	$0.00
80323		0%	23	$0.00
80360		0%	30	$0.00
80346		0%	30	$0.00
80355		0%	30	$0.00
80361		0%	30	$0.00
80365		0%	30	$0.00
80356		0%	30	$0.00
80373		0%	30	$0.00
80366		0%	30	$0.00
80348		0%	30	$0.00
80359		0%	30	$0.00
80358		0%	30	$0.00
80345		0%	30	$0.00
80324		0%	30	$0.00
80363		0%	30	$0.00
80353		0%	30	$0.00
80368		0%	23	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDZEVA, ANNA (CEO)

Same official

Other billing entities under DZEVA, ANNA

Full network →

Provider	Location	Paid
Spector Scientific Lab INC.	Deerfield Beach, FL	$1.62M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.